Akums Drugs & Pharmaceuticals saw a rise in its stock price, trading at Rs. 911.65, up by 4.10 points or 0.45% from its previous close of Rs. 907.55 on the BSE.

The stock opened at Rs. 948.95, hitting a high of Rs. 948.95 and a low of Rs. 910.30 during the session, with 7702 shares exchanged.

The BSE Group 'B' stock, with a face value of Rs. 2, achieved a 52-week high of Rs. 1174.85 on August 20, 2024, and a 52-week low of Rs. 724.50 on August 6, 2024. Over the last week, its high and low were Rs. 948.95 and Rs. 849.00, respectively. The company’s current market cap is Rs. 14,441.69 crore.

The promoter group holds 84.91% of the company, while 15.09% is owned by non-institutional investors.

Akums Drugs has been granted a Patent Certificate by the Patent Office of the Government of India on September 12, 2024. The patent, titled 'Room Stable Hydroxyurea Oral Suspension,' is valid for 20 years under the Patents Act of 1970.

This patented formulation represents a major advancement in treating Sickle Cell Disease (SCD) by solving the storage and accessibility issues of Hydroxyurea, further highlighting Akums’ role as a leader in pharmaceutical innovation.

As a CDMO, Akums Drugs & Pharmaceuticals provides a broad range of pharmaceutical products and services in India and internationally.